US FDA 510(k) Submission Consultants for Medical Devices

A US FDA 510(k) submission is the premarket notification most Class II and some Class I devices need before they can be sold in the United States. Medfins International helps manufacturers in India and abroad choose a sound predicate, plan testing, prepare the eSTAR dossier, respond to FDA requests and complete establishment registration, device listing and QMSR readiness.

What is a 510(k) premarket notification?

A 510(k) is a premarket submission to the US Food and Drug Administration (FDA) showing that your device is substantially equivalent to a legally marketed predicate device. The legal basis is section 510(k) of the Federal Food, Drug, and Cosmetic Act and 21 CFR Part 807 Subpart E. Once the FDA issues a substantially equivalent (SE) decision, the device is “cleared” for marketing.

Substantial equivalence means the same intended use and either the same technological characteristics, or different characteristics that do not raise different questions of safety and effectiveness, supported by performance data.

Who needs a US FDA 510(k)?

• Manufacturers introducing a Class II device (and certain Class I devices that are not exempt) to the US market for the first time.
• Companies changing the intended use, design, materials or technology of a cleared device in a way that could significantly affect safety or effectiveness.
• Specification developers and relabellers in some situations, depending on who is responsible for the device design.
• Foreign manufacturers, including Indian exporters, who must also register their establishment and appoint a US Agent.

Classification and choosing the right pathway

FDA classifies devices as Class I, II or III through product codes and regulation numbers in 21 CFR Parts 862 to 892. Most Class I and some Class II devices are 510(k)-exempt; most Class II devices need a 510(k); Class III devices generally need Premarket Approval (PMA). Novel low-to-moderate risk devices without a predicate may use the De Novo pathway.

Within the 510(k) programme there are Traditional, Special and Abbreviated types. A Special 510(k) may suit certain modifications to your own cleared device, while an Abbreviated 510(k) leans on guidance documents and recognised consensus standards. Where the route is uncertain, a Pre-Submission (Q-Sub) meeting lets you obtain FDA feedback before investing in testing.

Documents required in a 510(k)

• Device description, indications for use and labelling (including the IFU).
• Predicate comparison and substantial equivalence discussion.
• Performance testing: bench, electrical safety and EMC (IEC 60601 series), biocompatibility (ISO 10993), sterilisation and shelf life as applicable.
• Software and cybersecurity documentation for software functions and connected devices.
• Clinical or animal data only where bench testing cannot demonstrate equivalence.
• Declarations of conformity to FDA-recognised standards and a 510(k) summary or statement.

eSTAR is mandatory

Since 1 October 2023, 510(k) submissions must be prepared using the FDA’s electronic Submission Template And Resource (eSTAR), unless exempted, and submitted electronically. The eSTAR structure replaces the old Refuse to Accept checklist with a technical screening step, so a complete, internally consistent template is essential.

510(k) process: step by step

1. Regulatory strategy: confirm classification, product code, pathway and candidate predicates.
2. Optional Pre-Submission to agree testing and clinical data expectations with FDA.
3. Testing plan and execution with accredited laboratories against recognised standards.
4. eSTAR compilation, including the substantial equivalence argument and labelling.
5. MDUFA user fee payment and small business determination where eligible.
6. Submission and technical screening, followed by substantive review.
7. Additional Information (AI) response within the allowed period if FDA places the file on hold.
8. SE decision, then establishment registration and device listing before commercial distribution.

User fees, registration and the US Agent

A 510(k) attracts a MDUFA user fee that FDA revises each fiscal year (1 October to 30 September). The small business fee is roughly a quarter of the standard fee. Because amounts change every fiscal year, we confirm the current fee on the FDA website before filing. Qualifying small businesses, including foreign firms with the required tax documentation, can apply for reduced fees.

Establishments that manufacture, relabel or export devices for the US must complete establishment registration and device listing through the FDA Unified Registration and Listing System (FURLS), pay the annual registration fee and renew between 1 October and 31 December each year. Foreign establishments must name a US Agent who resides or maintains a place of business in the United States.

Quality system: the QMSR

From 2 February 2026, 21 CFR Part 820 is the Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 by reference. FDA inspections of US and foreign sites now assess compliance against the QMSR, so an ISO 13485 system with the FDA-specific additions (such as complaint, labelling and records requirements) is the practical baseline.

Timelines and what affects them

Under MDUFA performance goals, FDA aims to reach a decision on a 510(k) within 90 FDA review days, but the clock stops while a file is on hold for additional information. Total elapsed time depends on predicate strength, testing readiness, the quality of the eSTAR and how quickly deficiencies are answered.

Common reasons for delays and queries

• Weak or split predicates, or differences in indications for use that are not justified.
• Test reports that do not match the final device configuration or recognised standard versions.
• Missing cybersecurity, software or reprocessing documentation.
• Inconsistent labelling claims across the eSTAR sections.
• Biocompatibility endpoints not justified for the nature and duration of contact.

How Medfins International supports your 510(k)

We build the regulatory strategy, identify and assess predicates, draft test plans, review laboratory reports and compile the eSTAR. We then manage FDA correspondence, AI responses, FURLS registration and listing, and coordinate with your US Agent.

Because the QMSR is built on ISO 13485, many clients pair their submission with ISO 13485:2016 certification or MDSAP, and use internal audit support to prepare for FDA inspection. Contact us for a pathway assessment.

Frequently asked questions